Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030, driven by the rising prevalence of infectious diseases, such as tuberculosis and COVID-19, and technological advancements.

These are the latest findings of Vision Research Reports (Pune, MH, India), a market research company.

The rising prevalence of multi-drug resistant infections is creating the need for early diagnosis of infectious diseases. For instance, MDR infections are highly common in ICU patients, and the prevalence of MDR infections in critically ill SARS-CoV-2 patients ranged between 14% and 50%. Delay in diagnosis and treatment with antibiotics before the infection is diagnosed is leading to further increase in the prevalence of drug resistant-bacteria, creating a lucrative growth opportunity for the infectious disease IVD market. Market players are also launching a significant number of products to meet the growing demand.

Based on application, the COVID-19 segment dominated the global infectious disease IVD market in 2021 with the highest revenue share of more than 42.52%. This can be attributed to the increased adoption of SARS-CoV-2 testing to limit the spread of infection. Furthermore, government initiatives to enhance public testing along with the launch of innovative products acted as one of the major drivers for the segment’s growth. Going forward, the human immunodeficiency virus (HIV) segment is anticipated to witness significant growth, as a result of the rising prevalence of HIV and the resulting demand for tests for diagnosis and detection. The fast growth rate of TB and HIV segments can be attributed to enhanced testing. Furthermore, influenza testing in the respiratory virus segment has also picked up pace owing to the launch of new diagnostic tests that allow testing of SARS-CoV-2 as well as influenza with differentiation between the two conditions to expedite treatment.

Based on product, the reagents segment held the highest share of more than 66.4% of the overall revenue of the infectious disease IVD market in 2021 due to the high-volume usage of reagents for conducting tests. Moreover, the COVID-19 testing programs to confirm positive, as well as negative results have escalated the usage of reagents. Based on test location, the central laboratories segment dominated the global infectious disease IVD market in 2021 with the highest revenue share of more than 54.96%. The high demand for faster turnaround time has escalated the demand for point-of-care tests. COVID-19 has strengthened the segment’s growth and created higher demand for these products. The rapid turnaround time and low complexity are lending the products in this segment a competitive edge. Hospitals are considered niche healthcare settings. The most significant advantage of hospitals conducting infectious disease IVD tests is that they can provide test results even in emergencies. Since IVD tests are becoming simpler in use, the adoption rate in hospitals has increased. With the increased number of hospitals aiming to provide all services under one roof for patients, the advancements in hospital laboratories become essential to meet the changing patient demands.

Based on technology, the molecular diagnostics segment dominated the global infectious disease IVD market in 2021 with the highest revenue share of more than 44.78%. Molecular diagnostics are used for all major parasitic, bacterial, and viral infections. These tests are advanced and overcome the drawbacks, such as irregular growth of microorganisms in manually prepared media, longer turnaround duration, and poor sensitivity of traditional testing methods. The immunoassay technology segment is estimated to expand at a steady CAGR from 2022 to 2030. Companies are focusing on the development and commercialization of immunoassays for COVID-19 diagnosis, due to increased demand for rapid point-of-care tests. Increasing use of serology testing, such as ELISA, for detection of the novel coronavirus, is anticipated to boost the growth of the immunoassay technology segment.

Based on region, North America dominated the global infectious disease IVD market in 2021 with the highest revenue share of more than 42.36%. The North American infectious disease IVD market is expected to expand further at a significant pace over the forecast period due to the presence of a favorable & flexible regulatory framework, presence of major industry players, and focus on increasing disease surveillance by conducting more tests in the region. The Asia Pacific infectious disease IVD market is estimated to register the fastest CAGR from 2022 to 2030 due to the high prevalence of infectious diseases in the region. Furthermore, growing healthcare access in developing economies, such as India, is boosting the region’s growth. In India, consumer awareness has led to an increase in the number of tests & diagnostics for infectious diseases over the past few years. Molecular diagnostics testing was earlier affordable only to the upper class, although the country’s rapid economic development has increased the purchasing power of people, leading to a rise in market penetration of infectious diseases molecular diagnostics in India. In addition, the demand for better diagnostics is expected to increase the growth potential of the infectious diseases molecular diagnostics market in India. The rising geriatric population in nations, such as Japan, is also acting as a key growth driver for the adoption of IVD tests in the infectious disease IVD market in the Asia Pacific region.

Related Links:
Vision Research Reports 

Visit expo >

Gold Member

Flocked Fiber Swabs

Puritan® Patented HydraFlock®

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Biological Indicator Vials

BI-O.K.

New

Total 25-Hydroxyvitamin D₂ & D₃ Assay

Total 25-Hydroxyvitamin D₂ & D₃ Assay